In a recent systematic analysis of DS in R/R AML patients treated with ivosidenib and enasidenib on behalf of the US FDA, a higher relative risk of DS was associated with peripheral blast count ≥25%, bone marrow blast count ≥48%, and concurrent TET2 mutations (45). This evidence concerns the gene TET2 and acute myeloid leukemia.